10% Triple Virally Reduced Intravenous Immunoglobulin Solution
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 10% Triple Virally Reduced Intravenous Immunoglobulin Solution, covering 2021-05-03 to 2021-05-03. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura [Phase 2]